Industry Experts

Peter currently serves as Site Head at Pace Life Sciences in Boston, a CDMO specializing in the development of small molecules, biologics, and genetic medicines. He also serves as President of Vector Sciences, Inc., a biotech startup developing vaccines, cancer therapies, and gene therapeutics using its Rheovax platform. Earlier, he was Managing Director of U.S. operations at Batavia Biosciences and Virology Director at Beth Israel Deaconess Medical Center/Harvard Medical School. Peter led development of novel platforms including the Ad26 technology used in Johnson & Johnson’s licensed Ebola and COVID-19 vaccines. He holds a PhD from the University of Amsterdam, has authored more than 70 publications, holds multiple patents, and co-founded two biotech startups.